Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124720 | 0.89 | TRPA1 (0.41) | TRPA1ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL6710153 | 0.86 | TRPA1 (0.43) | TRPA1ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL6713877 | 0.86 | TRPA1 (0.43) | TRPA1ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL6833424 | 0.84 | TDP1 (0.46) | ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6834385 | 0.83 | SERPINE1 (0.51) | KMT2AALBNR1H4NHERF1 | |
| SCHEMBL6834154 | 0.82 | KMT2A (0.49) | KMT2AMEN1ALBNR1H4NHERF1 | |
| SCHEMBL6833137 | 0.81 | MAP3K5 (0.44) | POLBKMT2ANSD2ALBNR1H4 | |
| SCHEMBL6835708 | 0.80 | CCKAR (0.51) | LMNASMN1; SMN2NHERF1 | |
| SCHEMBL6833284 | 0.79 | PKM (0.39) | ALDH1A1POLBKMT2AMEN1NSD2 | |
| SCHEMBL6835564 | 0.79 | RXFP1 (0.42) | POLBKMT2AALBNR1H4NHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | TRPA1 377/4885ALDH1A1 170/4885POLB 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.